Abstract
We recently reported the SART3 tumour-rejection antigen as possessing tumour epitopes capable of inducing HLA-class I-restricted cytotoxic T lymphocytes (CTLs). This study investigated expression of the SART3 antigen in breast cancer to explore an appropriate molecule for use in specific immunotherapy of breast cancer patients. The SART3 antigen was detected in all of the breast cancer cell lines tested, 30 of 40 (75%) breast cancer tissue samples, and 0 of 3 non-tumourous breast tissue samples. SART3 derived peptides at positions 109–118 and 315–323 induced HLA-A24 restricted CTLs that reacted to breast cancer cells from the peripheral blood mononuclear cells (PBMCs) of breast cancer patients. Therefore, the SART3 antigen and its peptides could be an appropriate molecule for use in specific immunotherapy of the majority of HLA-A24-positive breast cancer patients. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
David CL, Peter SG, George EP, Selwyn OR and Timothy JE (1995) Tumor-specific and HLA-A2-restricted cytolysis tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 155: 4486–4491
Gaugler B, van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, de Plaen E, Lethe B, Brasseur F and Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179: 921–930
Imanishi T, Akazawa T, Kimura A, Tokunaga K and Gojobori T (1992) Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: HLA 1991 1, Tsuji K, Aizawa M, Sasazuki (eds) pp 1065–1220, Oxford Scientific Publications: Oxford
Inoue H, Mori M, Honda M, Li J, Shibata K, Mimori K, Ueo H and Akiyoshi T (1995) The expression of tumor-rejection antigens of MAGE genes. Int J Cancer 62: 523–526
Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E and Rosenberg SA (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180: 347–352
Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E and Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154: 3961–3968
Kawamoto M, Shichijo S, Imai Y and Itoh K (1999) Expression of the SART1 tumor rejection antigen in breast cancer. Int J Cancer 80: 64–67
Kikuchi M, Nakao M, Inoue Y, Matsunaga K, Shichijo S, Yamana H and Itoh K (1999) Identification of a SART1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 81: 459–466
Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, de Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P and Boon T (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80: 219–230
Murayama K, Kogayashi T, Imaizumi T, Matsunaga K, Kuramoto T, Shigemori M, Shichijo S and Itoh K (2000) Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocyres by its peptide. J Immunotherapy 23: 511–518
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med 4: 328–332
Robbins PF, El-gamil M, Li YF, Kawakami Y, Loftus D, Appella E and Rosenberg SA (1996) A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183: 1185–1192
Robbins PF, El-gamil M, Li YF, Fitzgerald EB, Kawakami Y and Rosenberg SA (1997) The intronic region of an incompletely spliced gp 100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol 159: 303–308
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH and White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 4: 321–327
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712
Traverrsari C, Meazza R, Coppolecchia M, Basso S, Verrecchia A, van der Bruggen P, Ardizzoni A, Gsggero A and Ferrini S (1997) IFN-γ gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Therapy 4: 1029–1035
van der Bruggen P, Traversari C, Chomes P, Lurquin C, de Plaen E, van den Eynde B, Knuth A and Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647
van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boul P, de Smet C, Traversari C, Townsent A and Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24: 3038–3043
Vasso A, Vaios K, John SH and Ian FCM (1997) Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 159: 5211–5218
Vincenzo R, Catia T, Alessandro V, Marccella M, Pier N and Claudio B (1995) Expression of the MAGE gene family and metastatic human breast cancer: implication for tumor antigen-specific immunotherapy. Int. J. Cancer 64: 216–221
Yamauchi H, O’neill A, Gelman R, Carney W, Tenney DY, Hosch S and Hayes DF (1997) Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 2518–2525
Yang D, Nakao M, Shichijo S, Sasatomi T, Takatu H, Matsumoto H, Mori K, Yamana H, Shirouzu K and Itoh K (1999) A gene coding for a protein possessing shared tumor epitopes capable of inducing cytotoxic T lymphocytes in cancer patients. Cancer Res 59: 4056–4063
Zaks TZ and Rosenberg SA (1998) Immunization with a peptide epitope (p369–377) from HER-2/neu leads to peptide-specificity cytotoxic T lymphocytes that fail to recognize HER-2/neu+tumors. Cancer Res 58: 4902–4908
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Suefuji, Y., Sasatomi, T., Shichijo, S. et al. Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients. Br J Cancer 84, 915–919 (2001). https://doi.org/10.1054/bjoc.2000.1690
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1690
Keywords
This article is cited by
-
Unravelling transcriptomic complexity in breast cancer through modulation of DARPP-32 expression and signalling pathways
Scientific Reports (2023)
-
Oxygen atoms are critical in rendering THP-1 leukaemia cells susceptible to cold physical plasma-induced apoptosis
Scientific Reports (2017)
-
Tip110 interacts with YB-1 and regulates each other’s function
BMC Molecular Biology (2013)
-
Antitumor immunity of human SART3 gene vaccine against mouse tumor in vitro/vivo
Frontiers of Medicine in China (2008)